\select@language {french}
\contentsline {chapter}{\numberline {1}Introduction}{17}{chapter.1}
\contentsline {section}{\numberline {1.1}Principes de la mod\IeC {\'e}lisation pharmacocin\IeC {\'e}tique}{17}{section.1.1}
\contentsline {subsection}{\numberline {1.1.1}G\IeC {\'e}n\IeC {\'e}ralit\IeC {\'e}s}{17}{subsection.1.1.1}
\contentsline {subsection}{\numberline {1.1.2}Mod\IeC {\'e}lisation pharmacocin\IeC {\'e}tique par approche non-compartimentale}{19}{subsection.1.1.2}
\contentsline {subsubsection}{\numberline {1.1.2.1}Aire sous la courbe}{19}{subsubsection.1.1.2.1}
\contentsline {subsubsection}{\numberline {1.1.2.2}Fraction biodisponible}{20}{subsubsection.1.1.2.2}
\contentsline {subsubsection}{\numberline {1.1.2.3}Temps de r\IeC {\'e}sidence moyen}{20}{subsubsection.1.1.2.3}
\contentsline {subsubsection}{\numberline {1.1.2.4}Clairance}{22}{subsubsection.1.1.2.4}
\contentsline {subsubsection}{\numberline {1.1.2.5}Volume de distribution}{22}{subsubsection.1.1.2.5}
\contentsline {subsection}{\numberline {1.1.3}Mod\IeC {\'e}lisation pharmacocin\IeC {\'e}tique par approche compartimentale}{22}{subsection.1.1.3}
\contentsline {subsubsection}{\numberline {1.1.3.1}Mod\IeC {\`e}le mono-compartimental avec \IeC {\'e}limination d'ordre~1}{23}{subsubsection.1.1.3.1}
\contentsline {subsubsection}{\numberline {1.1.3.2}Mod\IeC {\`e}le mono-compartimental avec administration~\gls {EV}}{24}{subsubsection.1.1.3.2}
\contentsline {subsubsection}{\numberline {1.1.3.3}Correspondance avec l'analyse non-compartimentale}{25}{subsubsection.1.1.3.3}
\contentsline {subsubsection}{\numberline {1.1.3.4}Mod\IeC {\`e}le bicompartimental avec constantes de transfert d'ordre~1}{26}{subsubsection.1.1.3.4}
\contentsline {subsubsection}{\numberline {1.1.3.5}Mod\IeC {\`e}les avec \IeC {\'e}limination saturable}{28}{subsubsection.1.1.3.5}
\contentsline {paragraph}{\numberline {1.1.3.5.1}Mod\IeC {\`e}le m\IeC {\'e}canistique TMDD}{29}{paragraph.1.1.3.5.1}
\contentsline {paragraph}{\numberline {1.1.3.5.2}\IeC {\'E}limination de type Michaelis-Menten}{30}{paragraph.1.1.3.5.2}
\contentsline {paragraph}{\numberline {1.1.3.5.3}\IeC {\'E}limination d'ordre~0}{31}{paragraph.1.1.3.5.3}
\contentsline {subsection}{\numberline {1.1.4}Relation dose-concentration-effet d'un m\IeC {\'e}dicament}{31}{subsection.1.1.4}
\contentsline {subsection}{\numberline {1.1.5}Principes de l'estimation des param\IeC {\`e}tres d'un mod\IeC {\`e}le pharmacocin\IeC {\'e}tique}{33}{subsection.1.1.5}
\contentsline {subsubsection}{\numberline {1.1.5.1}Approche individuelle}{35}{subsubsection.1.1.5.1}
\contentsline {subsubsection}{\numberline {1.1.5.2}Approche de population}{35}{subsubsection.1.1.5.2}
\contentsline {section}{\numberline {1.2}Les anticorps monoclonaux th\IeC {\'e}rapeutiques}{40}{section.1.2}
\contentsline {subsection}{\numberline {1.2.1}G\IeC {\'e}n\IeC {\'e}ralit\IeC {\'e}s}{40}{subsection.1.2.1}
\contentsline {subsection}{\numberline {1.2.2}M\IeC {\'e}canismes impliqu\IeC {\'e}s dans la pharmacocin\IeC {\'e}tique des anticorps monoclonaux}{42}{subsection.1.2.2}
\contentsline {subsubsection}{\numberline {1.2.2.1}Absorption des anticorps monoclonaux}{42}{subsubsection.1.2.2.1}
\contentsline {subsubsection}{\numberline {1.2.2.2}\IeC {\'E}limination des anticorps monoclonaux}{43}{subsubsection.1.2.2.2}
\contentsline {subsubsection}{\numberline {1.2.2.3}Captation par endocytose}{43}{subsubsection.1.2.2.3}
\contentsline {subsubsection}{\numberline {1.2.2.4}R\IeC {\^o}le du FcRn dans l'\IeC {\'e}limination et de la distribution des anticorps monoclonaux}{43}{subsubsection.1.2.2.4}
\contentsline {subsubsection}{\numberline {1.2.2.5}\IeC {\'E}limination apr\IeC {\`e}s fixation sur la cible}{46}{subsubsection.1.2.2.5}
\contentsline {subsubsection}{\numberline {1.2.2.6}\IeC {\'E}limination li\IeC {\'e}e \IeC {\`a} l'immunisation du sujet trait\IeC {\'e} (immunog\IeC {\'e}nicit\IeC {\'e})}{46}{subsubsection.1.2.2.6}
\contentsline {subsection}{\numberline {1.2.3}Mod\IeC {\'e}lisation pharmacocin\IeC {\'e}tique des anticorps monoclonaux}{47}{subsection.1.2.3}
\contentsline {subsubsection}{\numberline {1.2.3.1}Dose-d\IeC {\'e}pendance et \IeC {\'e}limination non-lin\IeC {\'e}aire}{48}{subsubsection.1.2.3.1}
\contentsline {subsubsection}{\numberline {1.2.3.2}Facteurs de variabilit\IeC {\'e} interindividuelle de la pharmacocin\IeC {\'e}tique des anticorps monoclonaux.}{49}{subsubsection.1.2.3.2}
\contentsline {paragraph}{\numberline {1.2.3.2.1}Facteurs d\IeC {\'e}mographiques et biochimiques.}{49}{paragraph.1.2.3.2.1}
\contentsline {paragraph}{\numberline {1.2.3.2.2}Immunisation}{49}{paragraph.1.2.3.2.2}
\contentsline {subsection}{\numberline {1.2.4}Facteurs de variabilit\IeC {\'e} de la relation dose-concentration-effet des IgG}{50}{subsection.1.2.4}
\contentsline {subsection}{\numberline {1.2.5}M\IeC {\'e}thodes de mesure des concentrations des anticorps monoclonaux}{50}{subsection.1.2.5}
\contentsline {section}{\numberline {1.3}Le cetuximab}{52}{section.1.3}
\contentsline {subsection}{\numberline {1.3.1}Modes d'action du cetuximab}{52}{subsection.1.3.1}
\contentsline {subsection}{\numberline {1.3.2}Indications et posologie du cetuximab}{54}{subsection.1.3.2}
\contentsline {subsection}{\numberline {1.3.3}M\IeC {\'e}thodes de mesure des concentrations de cetuximab}{55}{subsection.1.3.3}
\contentsline {subsection}{\numberline {1.3.4}Pharmacocin\IeC {\'e}tique des anticorps anti-EGFR}{55}{subsection.1.3.4}
\contentsline {subsection}{\numberline {1.3.5}Relations dose-r\IeC {\'e}ponse et concentration-r\IeC {\'e}ponse du cetuximab}{56}{subsection.1.3.5}
\contentsline {chapter}{\numberline {2}Objectifs}{59}{chapter.2}
\contentsline {chapter}{\numberline {3}M\IeC {\'e}thodes}{61}{chapter.3}
\contentsline {section}{\numberline {3.1}D\IeC {\'e}veloppement et validation de la m\IeC {\'e}thode ELISA de dosage du cetuximab.}{61}{section.3.1}
\contentsline {subsection}{\numberline {3.1.1}Principes de l'ELISA indirect}{61}{subsection.3.1.1}
\contentsline {subsection}{\numberline {3.1.2}D\IeC {\'e}veloppement}{63}{subsection.3.1.2}
\contentsline {subsection}{\numberline {3.1.3}Validation de la m\IeC {\'e}thode}{64}{subsection.3.1.3}
\contentsline {subsubsection}{\numberline {3.1.3.1}Contr\IeC {\^o}le de dilution}{64}{subsubsection.3.1.3.1}
\contentsline {subsubsection}{\numberline {3.1.3.2}Sp\IeC {\'e}cificit\IeC {\'e}}{65}{subsubsection.3.1.3.2}
\contentsline {section}{\numberline {3.2}Mod\IeC {\'e}lisation de la pharmacocin\IeC {\'e}tique}{65}{section.3.2}
\contentsline {subsection}{\numberline {3.2.1}Choix de l'approche de mod\IeC {\'e}lisation}{65}{subsection.3.2.1}
\contentsline {subsection}{\numberline {3.2.2}Choix du mod\IeC {\`e}le structural et de variabilit\IeC {\'e} interindividuelle}{66}{subsection.3.2.2}
\contentsline {subsection}{\numberline {3.2.3}Choix du mod\IeC {\`e}le d'erreur r\IeC {\'e}siduelle}{66}{subsection.3.2.3}
\contentsline {subsection}{\numberline {3.2.4}S\IeC {\'e}lection des covariables significatives}{66}{subsection.3.2.4}
\contentsline {section}{\numberline {3.3}Analyse de survie sans progression}{67}{section.3.3}
\contentsline {section}{\numberline {3.4}Simulations}{68}{section.3.4}
\contentsline {section}{\numberline {3.5}Outils informatiques}{69}{section.3.5}
\contentsline {chapter}{\numberline {4}R\IeC {\'e}sultats}{71}{chapter.4}
\contentsline {section}{\numberline {4.1}\IeC {\'E}tude de la pharmacocin\IeC {\'e}tique du cetuximab chez l'Homme.}{71}{section.4.1}
\contentsline {subsection}{\numberline {4.1.1}Introduction}{71}{subsection.4.1.1}
\contentsline {subsection}{\numberline {4.1.2}Durant la dialyse r\IeC {\'e}nale (publication~I)}{71}{subsection.4.1.2}
\contentsline {subsection}{\numberline {4.1.3}Dans le cancer colorectal m\IeC {\'e}tastatique (publications~II et III)}{72}{subsection.4.1.3}
\contentsline {subsection}{\numberline {4.1.4}Conclusion sur la pharmacocin\IeC {\'e}tique du cetuximab chez l'Homme.}{77}{subsection.4.1.4}
\contentsline {section}{\numberline {4.2}Influence de la pharmacocin\IeC {\'e}tique du cetuximab sur son efficacit\IeC {\'e} (publication~III)}{78}{section.4.2}
\contentsline {subsection}{\numberline {4.2.1}Mod\IeC {\'e}lisation pharmacocin\IeC {\'e}tique-pharmacodynamique}{78}{subsection.4.2.1}
\contentsline {subsection}{\numberline {4.2.2}Influence de l'exposition au cetuximab sur la PFS}{79}{subsection.4.2.2}
\contentsline {subsection}{\numberline {4.2.3}Relation entre la toxicit\IeC {\'e} et la PFS}{81}{subsection.4.2.3}
\contentsline {subsection}{\numberline {4.2.4}Relation entre les concentrations r\IeC {\'e}siduelles et la PFS}{82}{subsection.4.2.4}
\contentsline {subsection}{\numberline {4.2.5}Conclusion}{84}{subsection.4.2.5}
\contentsline {section}{\numberline {4.3}Simulation des concentrations obtenues avec diff\IeC {\'e}rentes posologies de cetuximab (manuscrit IV)}{86}{section.4.3}
\contentsline {subsection}{\numberline {4.3.1}Contexte}{86}{subsection.4.3.1}
\contentsline {subsection}{\numberline {4.3.2}Simulations}{87}{subsection.4.3.2}
\contentsline {subsection}{\numberline {4.3.3}Analyses}{87}{subsection.4.3.3}
\contentsline {subsection}{\numberline {4.3.4}Conclusions}{88}{subsection.4.3.4}
\contentsline {section}{\numberline {4.4}\IeC {\'E}tude de l'absorption pulmonaire du cetuximab dans un mod\IeC {\`e}le murin (publication~V)}{88}{section.4.4}
\contentsline {subsection}{\numberline {4.4.1}Contexte}{88}{subsection.4.4.1}
\contentsline {subsection}{\numberline {4.4.2}Mod\IeC {\`e}le murin}{90}{subsection.4.4.2}
\contentsline {subsection}{\numberline {4.4.3}Mod\IeC {\'e}lisation de la pharmacocin\IeC {\'e}tique}{90}{subsection.4.4.3}
\contentsline {subsection}{\numberline {4.4.4}Conclusions}{91}{subsection.4.4.4}
\contentsline {chapter}{\numberline {5}Discussion}{93}{chapter.5}
\contentsline {chapter}{Bibliographie}{98}{chapter.5}
\contentsline {chapter}{Glossaire}{117}{chapter*.46}
